We are progressing ONS-5010, a developmental ophthalmic formulation of bevacizumab for the management of wet AMD, DME and BRVO. Outlook Therapeutics is a mature clinical-stage biopharmaceutical company striving to create the initial FDA-endorsed ophthalmic formulation of bevacizumab for utilization in retinal conditions. Our objective is to introduce ONS-5010 as the primary and exclusive sanctioned ophthalmic formulation of bevacizumab in the United States, Europe, Japan and other regions for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).
Outlook Therapeutics
Headquarters
United States of America